173 related articles for article (PubMed ID: 22356625)
21. [A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
Tamura T; Mizuyama Y; Shinto O; Nishihara T; Nakagawa H; Ono Y
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2732-4. PubMed ID: 21224695
[TBL] [Abstract][Full Text] [Related]
22. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
Charoentum C; Thongprasert S; Chewaskulyong B; Munprakan S
World J Gastroenterol; 2007 May; 13(20):2852-4. PubMed ID: 17569122
[TBL] [Abstract][Full Text] [Related]
23. [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
Wato M; Inaba T; Ishikawa H; Ishikawa S; Baba N; Miyoshi M; Senoh T; Nagano T; Takaguchi K; Watanabe S; Kawai K
Nihon Shokakibyo Gakkai Zasshi; 2010 Oct; 107(10):1676-85. PubMed ID: 20938119
[TBL] [Abstract][Full Text] [Related]
24. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
Saif MW; McGee PJ
JOP; 2005 Jul; 6(4):369-74. PubMed ID: 16006690
[TBL] [Abstract][Full Text] [Related]
25. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Müller S; Schütt P; Bojko P; Nowrousian MR; Hense J; Seeber S; Moritz T
Ann Hematol; 2005 Feb; 84(2):110-4. PubMed ID: 15340761
[TBL] [Abstract][Full Text] [Related]
26. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.
Chang Y; Mbeo G; Littman SJ
J Gastrointest Cancer; 2012 Sep; 43(3):505-7. PubMed ID: 21556724
[TBL] [Abstract][Full Text] [Related]
27. Chronic anemia resistant to erythropoietin in a patient treated with gemcitabine showing a hemolytic uremic syndrome (HUS).
Assi C; Lepage C; Jouve JL; Sgro C; Bedenne L
Gastroenterol Clin Biol; 2010 Nov; 34(11):640-2. PubMed ID: 21051168
[No Abstract] [Full Text] [Related]
28. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver.
Kirchhoff T; Zender L; Merkesdal S; Frericks B; Malek N; Bleck J; Kubicka S; Baus S; Chavan A; Manns MP; Galanski M
World J Gastroenterol; 2005 Feb; 11(8):1091-5. PubMed ID: 15754387
[TBL] [Abstract][Full Text] [Related]
29. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
[TBL] [Abstract][Full Text] [Related]
30. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
31. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
32. [Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
Vega J; Parodi C; Méndez GP; Goecke H
Rev Med Chil; 2013 Jun; 141(6):797-802. PubMed ID: 24121585
[TBL] [Abstract][Full Text] [Related]
33. [Hemolytic uremic syndrome following gemcitabine treatment].
Bourquin V; Guinand A; Haenni C; Giovannini M; Delouche D; Dettwiler S; Moll S
Rev Med Suisse; 2008 Apr; 4(154):1056-61. PubMed ID: 18557535
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).
Inaba Y; Arai Y; Yamaura H; Sato Y; Najima M; Aramaki T; Sone M; Kumada T; Tanigawa N; Anai H; Yoshioka T; Ikeda M;
Am J Clin Oncol; 2011 Feb; 34(1):58-62. PubMed ID: 20177362
[TBL] [Abstract][Full Text] [Related]
35. [A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine].
Eckel F; Lersch C; Erdmann J; Schmidt B; Schulte-Frohlinde E
Z Gastroenterol; 2000 Jul; 38(7):593-6. PubMed ID: 10965557
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Sakabe R; Ohge H; Sueda T
Ann Surg Oncol; 2011 Mar; 18(3):651-8. PubMed ID: 20945107
[TBL] [Abstract][Full Text] [Related]
37. [Gemcitabine in the treatment of 4 patients with cholangiocarcinoma].
Gallardo J; Cabrera E; Rubio B; González C; Cortés C
Rev Med Chil; 2001 Aug; 129(8):911-6. PubMed ID: 11680965
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
39. Clinical presentation and outcomes of patients with biliary malignancies: the Aga Khan University experience.
Kumar S; Masood N; Shaikh AJ; Valimuhammad AT; Haider G; Lal A; Niamatullah N
Asian Pac J Cancer Prev; 2009; 10(3):463-6. PubMed ID: 19640192
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma.
Gürlevik E; Fleischmann-Mundt B; Armbrecht N; Longerich T; Woller N; Kloos A; Hoffmann D; Schambach A; Wirth TC; Manns MP; Zender L; Kubicka S; Kühnel F
Hepatology; 2013 Sep; 58(3):1031-41. PubMed ID: 23686746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
